To our knowledge, this is the first study to appraise the cost-effectiveness of serplulimab plus chemotherapy in the first-line treatment of patients with PD-L1-positive advanced ESCC from the Chinese healthcare system perspective. Here, CD274 is linked to esophageal squamous cell carcinoma.